The CYP2D6 gene locus in South African Coloureds: Unique allele distributions, novel alleles and gene arrangements

European Journal of Clinical Pharmacology

Volumn 64, Issue 5, 2008, Pages 465-475

  Gaedigk, Andrea ^a   Coetsee, Christa ^b,c  

^a CHILDREN S MERCY HOSPITAL   (United States)

^b UNIVERSITY OF THE FREE STATE   (South Africa)

^c IQVIA   (United States)

Author keywords

Coloureds; CYP2D6; Gene rearrangements; Pharmacogenetics; Polymorphisms

Indexed keywords

CYTOCHROME P450 2D6;

ALLELISM; ARTICLE; ETHNIC GROUP; GENE DUPLICATION; GENE FREQUENCY; GENE LOCUS; GENE REARRANGEMENT; GENE SEQUENCE; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; HUMAN TISSUE; MOLECULAR CLONING; NUCLEOTIDE SEQUENCE; PHARMACOGENETICS; PHENOTYPE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SOUTH AFRICA;

AFRICAN CONTINENTAL ANCESTRY GROUP; CYTOCHROME P-450 CYP2D6; EUROPEAN CONTINENTAL ANCESTRY GROUP; GENE FREQUENCY; GENOTYPE; HUMANS; PHENOTYPE; POLYMERASE CHAIN REACTION; SOUTH AFRICA;

EID: 41149086705     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00228-007-0445-7     Document Type: Article

References (20)

1. Zanger UM, Raimundo S, Eichelbaum M (2004) Cytochrome P450 2D6: overview and update on pharmacology, genetics, biochemistry. Naunyn-Schmiedeberg's Arch Pharmacol 369:23-37
2. Sistonen J, Sajantila A, Lao O, Corander J, Barbujani G, Fuselli S (2007) CYP2D6 worldwide genetic variation shows high frequency of altered activity variants and no continental structure. Pharmacogenet Genomics 17:93-101
3. Kirchheiner J, Nickchen K, Bauer M, Wong M-L, Licinio J, Roots I et al (2004) Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug response. Mol Psychiatry 9:442-472
4. Spina E, de Leon J (2007) Metabolic drug interactions with newer antipsychotics: a comparative review. Basic Clin Pharmacol Toxicol 100:4-22
5. Ingelman-Sundberg M (2004) Genetic polymorphisms of cytochrome P4502D6 (CYP2D6): clinical consequences, evolutionary aspects and functional diversity. Pharmacogenomics J 5:6-13
6. Gaedigk A, Bradford LD, Marcucci KA, Leeder JS (2002) Unique CYP2D6 activity distribution and genotype-phenotype discordance in African Americans. Clin Pharmacol Ther 72:76-89
7. Wennerholm A, Johansson I, Hidestrand M, Bertilsson L, Gustafsson LL, Ingelman-Sundberg M (2001) Characterization of the CYP2D6*29 allele commonly present in a black Tanzanian population causing reduced catalytic activity. Pharmacogenetics 11:417-427
8. Daly AK, Fairbrother KS, Andreassen OA, London SJ, Idle JR, Steen VM (1996) Characterization and PCR-based detection of two different hybrid CYP2D7P/CYP2D6 alleles associated with the poor metabolizer phenotype. Pharmacogenetics 6:319-328
9. Panserat S, Mura C, Gerard N, Vincent-Viry M, Galteau MM, Jacq-Aigrain E et al (1995) An unequal cross-over event within the CYP2D gene cluster generates a chimeric CYP2D7/CYP2D6 gene which is associated with the poor metabolizer phenotype. Br J Clin Pharmacol 40:361-367
10. Gaedigk A, Ndjountché L, Divakaran K, Bradford LD, Zineh I, Oberlander TF et al (2007) Cytochrome P4502D6 (CYP2D6) gene locus heterogeneity: characterization of gene duplication events. Clin Pharmacol Ther 81:242-251
11. Gaedigk A, Simon SD, Pearce RE, Bradford LD, M.J. K, Leeder JS (2007) The CYP2D6 activity score: Translating genotype information into a qualitative measure of phenotype. Clin Pharmacol Ther DOI 10.1038/sj.clpt.6100406
12. Gaedigk A, Bradford LD, Alander SW, Leeder JS (2006) CYP2D6*36 gene arrangements within the CYP2D6 locus: Association of CYP2D6*36 with poor metabolizer status. Drug Metab Dispos 34:563-569
13. Gaedigk A, Gotschall RR, Forbes NS, Simon SD, Kearns GL, Leeder JS (1999) Optimization of cytochrome P4502D6 (CYP2D6) phenotype assignment using a genotyping algorithm based on allele frequency data. Pharmacogenetics 9:669-682
14. Gaedigk A, Gaedigk R, Leeder JS (2005) CYP2D7 splice variants in human liver and brain: Does CYP2D7 encode functional protein? Biochem Biophys Res Comm 336:1241-1250
15. Fukuda T, Maune H, Ikenaga Y, Naohara M, Fukuda K, Azuma J (2005) Novel structure of the CYP2D6 gene that confuses genotyping for the CYP2D6*5 allele. Drug Metab Pharmacokinet 20:345-350
16. Marcucci KA, Pearce RE, Crespi C, Leeder JS, Gaedigk A (2002) Characterization of cytochrome P450 2D6.1 (CYP2D6.1), CYP2D6.2 and CYP2D6.17 activities toward model CYP2D6 substrates dextromethorphan, bufuralol, and debrisoquine. Drug Metab Dispos 30:1-7
17. Shen H, He MM, Liu H, Wrighton SA, Wang L, Guo B et al (2007) Comparative metabolic capabilities and inhibitory profiles of CYP2D6.1, CYP2D6.10, and CYP2D6.17. Drug Metab Dispos 35:1292-1300
18. O'Neil WM, Gilfix BM, Markoglou N, Di Girolamo A, Tsoukas CM, Wainer IW (2000) Genotype and phenotype of cytochrome P450 2D6 in human immunodeficiency virus-positive patients and patients with acquired immunodeficiency syndrome. Eur J Clin Pharmacol 56:231-240
19. Aitken AE, Richardson TA, Morgan ET (2006) Regulation of drug-metabolizing enzymes and transporters in inflammation. Annu Rev Pharmacol Toxicol 46:123-149
20. Johansson I, Lundqvist E, Dahl M-L, Ingelman-Sundberg M (1996) PCR-based genotyping for duplicated and deleted CYP2D6 genes. Pharmacogenetics 6:351-355